High deaths in middle age -More facts and truth with Dr John Campbell...
(credits: Dr John Campbell) https://www.youtube.com/watch?v=htRavAZ6jVE
Excess mortality in England post Covid-19 pandemic: implications for secondary preventionhttps://www.sciencedirect.com/....science/article/pii/ countries, including the UK, have continued to experience an apparent excess of deaths long after the peaks associated with the COVID-19 pandemic in 2020 and 2021. Numbers of excess deaths estimated in this period are considerable. The UK Office for National Statistics (ONS) has calculated that there were 7.2% or 44,255 more deaths registered in the UK in 2022 OECD, UKhttps://stats.oecd.org/index.a....spx?queryid=104676Ex deaths in 2022, 52,514 (9.26%)This persisted into 2023 with 8.6% or 28,024 more deaths registered in the first six months of the year than expected.OECD, UK, weeks 1 – 44, 2023Excess deaths, 49,389 (9.44%)The causes of these excess deaths are likely to be multiple and could include the direct effects of Covid-19 infection,acute pressures on NHS acute services resulting in poorer outcomes from episodes of acute illness,and disruption to chronic disease detection and management.Further analysis by cause and by age- and sex-group may help quantify the relative contributions of these causes.Office for Health Improvement and Disparities3rd June 2022 to 30th June 2023Excess deaths for all causes were relatively greatest for 50–64 year olds (15% higher than expected)11% higher for 25–49 and under 25 year olds,and about 9% higher for over 65sSeveral causes3rd June 2022–30th June 2023All cardiovascular diseases, 12%Heart failure, 20%Ischaemic heart disease, 15Liver diseases, 19%Acute respiratory infections, 14%Diabetes, 13% For middle-aged adults (50–64)Cardiovascular diseases, 33% higher than expectedIschaemic heart disease, 44%Cerebrovascular disease, 40%Heart failure 39% higherDeaths involving acute respiratory infections, 43% higherDiabetes, deaths were 35% higherThe pattern now is one of persisting excess deaths which are most prominent in relative terms in middle-aged and younger adultsTimely and granular analyses are needed to describe such trends and so to inform prevention and disease management efforts. JP-S is Partner at Lane Clark & Peacock LLP, Chair of the Royal Society for Public Health and reports personal fees from Novo Nordisk and Pfizer Ltd outside of this submitted work.
